Linezolid Krka (Linezolid)

Linezolid is indicated for bacterial infections affecting the skin, respiratory tract, and resistant Gram‑positive organisms.

• Complicated skin and skin‑structure infections: effective against MRSA and other Gram‑positive pathogens, helping resolve infection and prevent spread.
• Community‑acquired and nosocomial pneumonia: provides coverage for typical and atypical respiratory bacteria, improving clinical outcomes.
• Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): offers an alternative to vancomycin for serious MRSA infections.
• Infections caused by vancomycin‑resistant Enterococcus (VRE): active against VRE strains where other options are limited.

• Linezolid binds to the 23S rRNA of the 50S ribosomal subunit, preventing the formation of the initiation complex required for bacterial protein synthesis. By inhibiting the early stage of translation, it halts bacterial growth without affecting human ribosomes, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms. This unique mechanism distinguishes it from other antibiotic classes and contributes to its activity against resistant strains.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Metallic taste: altered taste perception.
• Myelosuppression (reversible): mild decrease in blood cell counts.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: nerve pain or sensory loss with prolonged use.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Lactic acidosis: rare metabolic disturbance.
• Optic neuropathy: vision changes requiring immediate attention.

When prescribing Linezolid, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: assess liver enzymes before and during treatment.
• Concomitant serotonergic drugs: avoid or closely monitor for serotonin syndrome.
• Long‑term therapy (>14 days): perform regular complete blood count monitoring.
• Pregnancy and lactation: use only if potential benefits outweigh risks.
• Store at below 25 °C: keep in the original container, protect from moisture and light.

Linezolid interacts with several medicines; the severity of the interaction determines the management approach.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increased serotonergic activity may be hazardous.
• Rifampicin: induces metabolism, reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may potentiate anticoagulant effect, requiring INR monitoring.
• Erythromycin or clarithromycin: may increase linezolid levels, watch for toxicity.
• Carbamazepine and other enzyme‑inducing anticonvulsants: may alter linezolid exposure.